Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca, BMS Team To Develop Type 2 Diabetes Drug For Japan

This article was originally published in PharmAsia News

Executive Summary

Two multinational drug makers plan to develop a new Type 2 diabetes drug targeted at Japan. AstraZeneca and Bristol-Myers Squibb said they would jointly develop and market dapagliflozin as a once-daily treatment for the disease in Japan and in 2012 in the United States and Europe. AstraZeneca's international sales chief noted that treatment of the disease and associated complications cost Japanese more than $18.4 billion last year alone. Bruno Angelici said the two companies believe dapagliflozin has the potential to reduce the cost and the impact of Type 2 in Japan. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts